Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

Authors: Simpson, Colin R. ;

Kerr, Steven ;

Katikireddi, Srinivasa Vittal ;

McCowan, Colin;

Ritchie, Lewis;

Pan, Jiafeng;

Stock, Sarah J. ;

Rudan, Igor ;

Tsang, Ruby S. M.;

de Lusignan, Simon ;

Hobbs, F.D. Richard;

Akbari, Ashley;

Lyons, Ronan A.;

Robertson, Chris;

Sheikh, Aziz

Source: Nature Communications

Full text

: https://doi.org/10.1038/s41467-022-32264-6

Abstract

We investigated thrombocytopenic, thromboembolic and hemorrhagic events following a second dose of ChAdOx1 and BNT162b2 using a self-controlled case series analysis. We used a national prospective cohort with 2.0 million(m) adults vaccinated with two doses of ChAdOx or 1.6 m with BNT162b2. The incidence rate ratio (IRR) for idiopathic thrombocytopenic purpura (ITP) 14–20 days post-ChAdOx1 second dose was 2.14, 95% confidence interval (CI) 0.90–5.08. The incidence of ITP post-second dose ChAdOx1 was 0.59 (0.37–0.89) per 100,000 doses. No evidence of an increased risk of CVST was found for the 0–27 day risk period (IRR 0.83, 95% CI 0.16 to 4.26). However, few (≤5) events arose within this risk period. It is perhaps noteworthy that these events all clustered in the 7–13 day period (IRR 4.06, 95% CI 0.94 to 17.51). No other associations were found for second dose ChAdOx1, or any association for second dose BNT162b2 vaccination. Second dose ChAdOx1 vaccination was associated with increased borderline risks of ITP and CVST events. However, these events were rare thus providing reassurance about the safety of these vaccines. Further analyses including more cases are required to determine more precisely the risk profile for ITP and CVST after a second dose of ChAdOx1 vaccine.

Rights

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit: http://creativecommons.org/licenses/by/4.0/.

Cite as

Simpson, C., Kerr, S., Katikireddi, S., McCowan, C., Ritchie, L., Pan, J., Stock, S., Rudan, I., Tsang, R., de Lusignan, S., Hobbs, F., Akbari, A., Lyons, R., Robertson, C. & Sheikh, A. 2022, 'Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland', Nature Communications, 13(1), article no: 4800. https://doi.org/10.1038/s41467-022-32264-6

Downloadable citations

HTML BIB RIS

Identifiers

DOI: https://doi.org/10.1038/s41467-022-32264-6

Repository URI: http://hdl.handle.net/10023/25855